drugset / Trial / NCT03228277
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
Phase 2
Completed
25 enrolled
Konkuk University Medical Center
Hanmi Pharmaceutical Company Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage fluid.
Timeline
- Start
- 2017-07-17
- Primary completion
- 2018-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olmutinib | Small molecule | 800 mg | — |